Ligand Pharmaceuticals, Inc. (LGND) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

SAGE Therapeutics, Inc.

Ligand Pharmaceuticals, Inc.

Catalyst Pharmaceuticals, Inc.

TG Therapeutics, Inc.

Mirum Pharmaceuticals, Inc.

Day One Biopharmaceuticals, Inc.

MannKind Corp.

Viking Therapeutics, Inc.

Amylyx Pharmaceuticals, Inc.

89bio, Inc.

EQRx, Inc.

Why is Ligand Pharmaceuticals, Inc. ?

The company is Net-Debt Free

The company has declared positive results for the last 3 consecutive quarters

OPERATING CASH FLOW(Y) Highest at USD 123.57 MM
ROCE(HY) Highest at 17.13%
NET PROFIT(Q) At USD 36.68 MM has Grown at 157.25%

With ROE of 5.61%, it has a attractive valuation with a 3.83 Price to Book Value

Over the past year, while the stock has generated a return of 139.78%, its profits have risen by 22.1% ; the PEG ratio of the company is 4

High Institutional Holdings at 100%

These investors have better capability and resources to analyse fundamentals of companies than most retail investors.

Market Beating performance in long term as well as near term

Along with generating 139.78% returns in the last 1 year, the stock has outperformed S&P 500 in the last 3 years, 1 year and 3 months

Real-Time Research Report

Verdict Report

How much should you buy?

Overall Portfolio exposure to Ligand Pharmaceuticals, Inc. should be less than 10%
Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Ligand Pharmaceuticals, Inc. for you?

High Risk, High Return

Absolute

Risk Adjusted

Volatility

Ligand Pharmaceuticals, Inc.

139.78%

6.58

37.34%

S&P 500

25.41%

1.92

13.25%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

7.54%

EBIT Growth (5y)

39.42%

EBIT to Interest (avg)

-2.40

Debt to EBITDA (avg)

0.21

Net Debt to Equity (avg)

-0.26

Sales to Capital Employed (avg)

0.19

Tax Ratio

69.38%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

100.00%

ROCE (avg)

1.63%

ROE (avg)

3.89%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

3.83

EV to EBIT

76.52

EV to EBITDA

43.85

EV to Capital Employed

4.94

EV to Sales

13.47

PEG Ratio

3.96

Dividend Yield

ROCE (Latest)

6.46%

ROE (Latest)

5.61%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bullish

RSI

No Signal

Bollinger Bands

Bullish

Moving Averages

Bullish (Daily)

KST

Mildly Bearish

Bullish

Dow Theory

Bullish

OBV

Mildly Bearish

Mildly Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

26What is working for the Company

OPERATING CASH FLOW(Y)

Highest at USD 123.57 MM

ROCE(HY)

Highest at 17.13%

NET PROFIT(Q)

At USD 36.68 MM has Grown at 157.25%

RAW MATERIAL COST(Y)

Fallen by -9.89% (YoY

NET SALES(9M)

Higher at USD 226.85 MM

CASH AND EQV(HY)

Highest at USD 1,512.94 MM

INVENTORY TURNOVER RATIO(HY)

Highest at 3.27 times

DEBTORS TURNOVER RATIO(HY)

Highest at 5.62 times

-9What is not working for the Company

INTEREST(HY)

At USD 3.53 MM has Grown at 101.83%

NET SALES(Q)

At USD 51.72 MM has Fallen at -22.83%

Here's what is working for Ligand Pharmaceuticals, Inc.

Operating Cash Flow

Highest at USD 123.57 MM and Grown

In each year in the last three years

MOJO Watch

The company has generated higher cash revenues from business operations

Operating Cash Flows (USD MM)

Net Profit

At USD 36.68 MM has Grown at 157.25%

over average net sales of the previous four periods of USD 14.26 MM

MOJO Watch

Near term Net Profit trend is very positive

Net Profit (USD MM)

Cash and Eqv

Highest at USD 1,512.94 MM

in the last six Semi-Annual periods

MOJO Watch

Short Term liquidity is improving

Cash and Cash Equivalents

Inventory Turnover Ratio

Highest at 3.27 times

in the last five Semi-Annual periods

MOJO Watch

Company has been able to sell its inventory faster

Inventory Turnover Ratio

Debtors Turnover Ratio

Highest at 5.62 times

in the last five Semi-Annual periods

MOJO Watch

Company has been able to sell its Debtors faster

Debtors Turnover Ratio

Raw Material Cost

Fallen by -9.89% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Ligand Pharmaceuticals, Inc.

Net Sales

At USD 51.72 MM has Fallen at -22.83%

over average net sales of the previous four periods of USD 67.02 MM

MOJO Watch

Near term sales trend is extremely negative

Net Sales (USD MM)

Interest

At USD 3.53 MM has Grown at 101.83%

over previous Semi-Annual period

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (USD MM)